Combination Therapy for Mycoplasma genitalium, and New Insights Into the Utility of parC Mutant Detection to Improve Cure.
Lenka A VodstrcilErica L PlummerMichelle DoyleGerald L MurrayKaveesha BodiyabaduJorgen S JensenDavid WhileyEmma SweeneyDeborah A WilliamsonEric P F ChowChristopher K FairleyCatriona S BradshawPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2022)
Combination doxycycline + azithromycin achieved high cure for macrolide-susceptible infections. However, in the context of a high prevalence of the parC S83I mutation (23%) in macrolide-resistant infections, doxycycline + moxifloxacin cured only 85%. Infections that were wild-type for S83/D87 experienced high cure following doxycycline + moxifloxacin, supporting the use of a parC-resistance/susceptibility testing strategy in clinical care.